ClinicalTrials.gg
CompletedNCT04436640BE MOVINGUpdated Nov 5, 2026

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

A Phase 3 interventional study of Bimekizumab in Axial Spondyloarthritis, Ankylosing Spondylitis and r-axSpa, sponsored by UCB Biopharma SRL. Completed at 75 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
508
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Axial Spondyloarthritis by UCB S.A. — 2 open to participants now, 2 under way, none of them phase 3. Axial Spondyloarthritis · UCB S.A..

Enrollment
2nd of 11
508 · median 274
Started
2020
with 1 other
Phase 3
5 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Axial Spondyloarthritis by UCB S.A., this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 11th registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

2 of the 13 studies in Axial Spondyloarthritis by UCB S.A. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Axial Spondyloarthritis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).

03

Conditions studied

  • Axial Spondyloarthritis
  • Ankylosing Spondylitis
  • r-axSpa
  • Nr-axSpa

Keywords

  • AxSpa
  • Radiographic
  • Non-radiographic
  • AS
  • Bimekizumab
  • Axial spondyloarthritis
  • Ankylosing spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
  • In the opinion of the Investigator, the study participant is expected to benefit from participation in this extension study
  • Study participant completed AS0010 (NCT03928704) or AS0011 (NCT03928743)

Exclusion criteria

Exclusion Criteria:

  • Female study participants who plan to become pregnant during the study or within 20 weeks following final dose of Medicinal Product (IMP). Male study participants who are planning a partner pregnancy during the study or within 20 weeks following the final dose
  • Study participants who meet any withdrawal criteria in AS0010 or AS0011. For any study participant with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder study, the Medical Monitor must be consulted prior to the study participant's entry into AS0014
  • Study participant has a positive or indeterminate interferon gamma release assay (IGRA) in AS0010 or AS0011, unless appropriately evaluated and treated
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
508 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects will receive bimekizumab throughout the Treatment Period.

    Drug: Bimekizumab

Interventions

  • Subjects will receive bimekizumab at prespecified time-points.

    Also known as: BKZ, UCB4940

06

What researchers measure

Primary outcomes

  1. Percentage of participants with treatment-emergent adverse events (TEAEs) during the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

  2. Percentage of participants with serious adverse events (SAEs) during the study

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalisation or prolongation of existing hospitalisation * Is a congenital anomaly or birth defect * Is an infection that requires treatment with parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

  3. Percentage of participants with with treatment-emergent adverse Events (TEAEs) leading to withdrawal from the study

    Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

Secondary outcomes

  1. Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 28

    ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain. The domains are: * Patient's Global Assessment of Disease Activity (PGADA) * Pain assessment (the total spinal pain, NRS score) * Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))- * Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 concerning morning stiffness intensity and duration)

    Time frame: Week 28

  2. Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 52

    ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain. The domains are: * Patient's Global Assessment of Disease Activity (PGADA) * Pain assessment (the total spinal pain, NRS score) * Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI)) * Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))

    Time frame: Week 52

  3. Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 112

    ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain. The domains are: * Patient's Global Assessment of Disease Activity (PGADA) * Pain assessment (the total spinal pain, NRS score) * Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI)) * Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))

    Time frame: Week 112

  4. Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 28

    ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain. The domains are: * Patient's Global Assessment of Disease Activity (PGADA) * Pain assessment (the total spinal pain, NRS score) * Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI)) * Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))

    Time frame: Week 28

  5. Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 52

    ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain. The domains are: * Patient's Global Assessment of Disease Activity (PGADA) * Pain assessment (the total spinal pain, NRS score) * Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI)) * Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))

    Time frame: Week 52

  6. Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 112

    ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain. The domains are: * Patient's Global Assessment of Disease Activity (PGADA) * Pain assessment (the total spinal pain, NRS score) * Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI)) * Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))

    Time frame: Week 112

  7. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 28

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

  8. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 52

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

  9. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 112

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

  10. Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 28

    The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of \<=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS40 domains.

    Time frame: Week 28

  11. Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 52

    The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of \<=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

    Time frame: Week 52

  12. Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 112

    The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of \<=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

    Time frame: Week 112

  13. Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 28

    The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below: 0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP \[mg/L\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

    Time frame: Week 28

  14. Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 52

    The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below: 0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP \[mg/L\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

    Time frame: Week 52

  15. Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 112

    The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below: 0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP \[mg/L\] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.+ 1)

    Time frame: Week 112

  16. Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 28

    The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS40 domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

    Time frame: Week 28

  17. Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 52

    The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

    Time frame: Week 52

  18. Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 112

    The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

    Time frame: Week 112

  19. Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 28

    The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

  20. Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 52

    The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

  21. Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 112

    The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

  22. Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 28

    Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

  23. Change from Baseline in nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 52

    Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

  24. Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 112

    Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

  25. Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 28

    The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

  26. Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 52

    The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

  27. Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 112

    The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

  28. Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 28

    There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

  29. Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 52

    There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

  30. Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 28

    The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

  31. Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 52

    The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

  32. Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 112

    The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

  33. Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 28

    The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

  34. Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 52

    The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

  35. Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 112

    The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

  36. Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 112

    There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

    Time frame: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

07

Study locations

75 sites
  • As0014 50062
    Glendale, Arizona 85306, United States
  • As0014 50052
    Phoenix, Arizona 85032, United States
  • As0014 50060
    Upland, California 91786, United States
  • As0014 50059
    Ormond Beach, Florida 32174, United States
  • As0014 50056
    Sarasota, Florida 34239, United States
  • As0014 50015
    Hagerstown, Maryland 21740, United States
  • As0014 50016
    St Louis, Missouri 63141, United States
  • As0014 50055
    Portland, Oregon 97239, United States
  • As0014 50020
    Duncansville, Pennsylvania 16635, United States
  • As0014 50057
    Dallas, Texas 75231, United States
  • As0014 40004
    Brussels, Belgium
  • As0014 40003
    Genk, Belgium
  • As0014 40001
    Ghent, Belgium
  • As0014 40006
    Plovdiv, Bulgaria
  • As0014 40007
    Plovdiv, Bulgaria
  • As0014 40005
    Sofia, Bulgaria
  • As0014 40008
    Sofia, Bulgaria
  • As0014 20040
    Beijing, China
  • As0014 20021
    Chengdu, China
  • As0014 20019
    Guangzhou, China
  • As0014 20034
    Hefei, China
  • As0014 20024
    Nanjing, China
  • As0014 20018
    Shanghai, China
  • As0014 20020
    Shanghai, China
  • As0014 20026
    Shanghai, China
  • As0014 20025
    Wenzhou, China
  • As0014 40011
    Brno, Czechia
  • As0014 40009
    Pardubice, Czechia
  • As0014 40013
    Prague, Czechia
  • As0014 40014
    Prague, Czechia
  • As0014 40015
    Prague, Czechia
  • As0014 40016
    Prague, Czechia
  • As0014 40010
    Uherské Hradiště, Czechia
  • As0014 40012
    Zlín, Czechia
  • As0014 40018
    Boulogne-Billancourt, France
  • As0014 40022
    Limoges, France
  • As0014 40025
    Berlin, Germany
  • As0014 40029
    Hamburg, Germany
  • As0014 40024
    Hanover, Germany
  • As0014 40027
    Herne, Germany
  • As0014 40078
    Leipzig, Germany
  • As0014 40026
    Ratingen, Germany
  • As0014 40032
    Debrecen, Hungary
  • As0014 40031
    Szeged, Hungary
  • As0014 40033
    Székesfehérvár, Hungary
  • As0014 20035
    Bunkyō City, Japan
  • As0014 20030
    Chūōku, Japan
  • As0014 20039
    Iruma-gun, Japan
  • As0014 20036
    Kawachi-Nagano, Japan
  • As0014 20045
    Kita-gun, Japan
  • As0014 20065
    Kitakyushu, Japan
  • As0014 20037
    Osaka, Japan
  • As0014 20084
    Saga, Japan
  • As0014 20048
    Saitama, Japan
  • As0014 20031
    Sapporo, Japan
  • As0014 20032
    Suita, Japan
  • As0014 40034
    Amsterdam, Netherlands
  • As0014 40038
    Elblag, Poland
  • As0014 40042
    Krakow, Poland
  • As0014 40037
    Lublin, Poland
  • As0014 40044
    Poznan, Poland
  • As0014 40040
    Torun, Poland
  • As0014 40041
    Warsaw, Poland
  • As0014 40039
    Wroclaw, Poland
  • As0014 40043
    Wroclaw, Poland
  • As0014 40045
    A Coruña, Spain
  • As0014 40046
    Córdoba, Spain
  • As0014 40048
    Santiago de Compostela, Spain
  • As0014 40049
    Seville, Spain
  • As0014 40052
    Ankara, Turkey (Türkiye)
  • As0014 40053
    Ankara, Turkey (Türkiye)
  • As0014 40050
    Istanbul, Turkey (Türkiye)
  • As0014 40057
    Edinburgh, United Kingdom
  • As0014 40056
    Leeds, United Kingdom
  • As0014 40055
    Norwich, United Kingdom
08

References and documents

Publications

  • Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, de Peyrecave N, Vaux T, White K, Deodhar A, van der Horst-Bruinsma I. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis. 2024 Nov 14;83(12):1722-1730. doi: 10.1136/ard-2024-225933. PubMed 38977276 ↗
  • Ramiro S, Poddubnyy D, Mease PJ, Lopez-Medina C, Kim M, Massow U, Taieb V, Kragstrup TW, McGonagle D. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025 Oct 22;11(4):e005969. doi: 10.1136/rmdopen-2025-005969. PubMed 41125403 ↗
  • Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Morup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. 2026 Aug 1:jrheum.2026-0104. doi: 10.3899/jrheum.2026-0104. Online ahead of print. PubMed 42386286 ↗
  • Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Coarse J, Prajapati C, Manente M, Marten A, Gensler LS. Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies. J Rheumatol. 2026 Aug 1:jrheum.2026-0113. doi: 10.3899/jrheum.2026-0113. Online ahead of print. PubMed 42297437 ↗
  • Maksymowych WP, Ramiro S, Poddubnyy D, Baraliakos X, Lambert RGW, Massow U, Vaux T, Prajapati C, Marten A, de Peyrecave N, Ostergaard M. Impact of Dual Interleukin-17A and Interleukin-17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open-Label Extension. Arthritis Rheumatol. 2026 Sep 14. doi: 10.1002/art.70336. Online ahead of print. PubMed 42740449 ↗
  • Ramiro S, Proft F, Sengupta R, van Tubergen A, Molto A, Gensler LS, Kishimoto M, Taieb V, Kavanagh S, Evans S, Navarro-Compan V. Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years. Arthritis Res Ther. 2026 Jan 19;28(1):40. doi: 10.1186/s13075-026-03729-6. PubMed 41555451 ↗
  • Navarro-Compan V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K, Deodhar A, de la Loge C, Prajapati C, Kavanagh S, Marzo-Ortega H. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. 2026 May 13;12(2):e006670. doi: 10.1136/rmdopen-2025-006670. PubMed 42128532 ↗
  • Mease PJ, Merola JF, Magrey M, Nash P, Poddubnyy D, Lebwohl M, Bajracharya R, Ink B, Marten A, Manente M, Peterson L, White K, Gensler LS. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. RMD Open. 2026 Mar 10;12(1):e006174. doi: 10.1136/rmdopen-2025-006174. PubMed 41807031 ↗
  • Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 Nov 28;11(4):e006013. doi: 10.1136/rmdopen-2025-006013. PubMed 41314667 ↗
  • Mease PJ, Gensler LS, Orbai AM, Warren RB, Bajracharya R, Ink B, Marten A, Massow U, Shende V, Manente M, Peterson L, White K, Landewe R, Poddubnyy D. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 2025 Apr 6;11(2):e005026. doi: 10.1136/rmdopen-2024-005026. PubMed 40194794 ↗

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Aug 2026, 73 months.

Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 73 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 18, 2020
StartActual
Jun 16, 2020
Primary completionActual
Aug 9, 2026
CompletionActual
Aug 9, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Maksymowych WP, Ramiro S, Poddubnyy D, Baraliakos X, Lambert RGW, Massow U, Vaux T, Prajapati C, Marten A, de Peyrecave N, Ostergaard M. Impact of Dual Interle… PubMed 42740449 ↗
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Publications Results publication added: Maksymowych WP, Ramiro S, Poddubnyy D, Baraliakos X, Lambert RGW, Massow U, Vaux T, Prajapati C, Marten A, de Peyrecave N, Ostergaard M. Impact of Dual Interle… PubMed 42740449 ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04436640
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
Jun 16, 2020
Primary completion
Aug 9, 2026
Completion
Aug 9, 2026
Last update
Nov 5, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion